Drug discovery for duchenne muscular dystrophy via utrophin promoter activation screening

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Moorwood, Catherine ^a,c   Lozynska, Olga ^b   Suri, Neha ^a,d   Napper, Andrew D ^b,e   Diamond, Scott L ^b   Khurana, Tejvir S ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA SCHOOL OF DENTAL MEDICINE   (United States)

^d Global Prior Art   (United States)

^e NEMOURS ALFRED I DUPONT HOSPITAL FOR CHILDREN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APIGENIN; CHRYSIN; CLORGYLINE; EQUILIN; HESPERETIN; KAEMPFEROL; KAWAIN; LEFLUNOMIDE; NABUMETONE; PHENAZOPYRIDINE; PIPERINE; RESVERATROL; RILUZOLE; TIABENDAZOLE; UTROPHIN;

ARTICLE; CELL ASSAY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG APPROVAL; DRUG MARKETING; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DUCHENNE MUSCULAR DYSTROPHY; GENE; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENETIC SCREENING; HUMAN; HUMAN CELL; MUTATOR GENE; PROCESS DEVELOPMENT; PROMOTER REGION; UPREGULATION; UTROPHIN A GENE; UTROPHIN GENE; VALIDATION PROCESS; BIOAVAILABILITY; CELL LINE; DRUG EFFECT; GENETICS; HIGH THROUGHPUT SCREENING; METHODOLOGY; MOLECULAR LIBRARY; REPRODUCIBILITY;

MUS;

BIOLOGICAL AVAILABILITY; CELL LINE; DRUG EVALUATION, PRECLINICAL; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MUSCULAR DYSTROPHY, DUCHENNE; PROMOTER REGIONS, GENETIC; REPRODUCIBILITY OF RESULTS; SMALL MOLECULE LIBRARIES; UP-REGULATION; UTROPHIN;

EID: 80054779433     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026169     Document Type: Article

References (63)

1. Hoffman EP, Brown RH Jr, Kunkel LM, (1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
2. Engel AG, Franzini-Armstrong C, (2004) Myology: Basic and Clinical McGraw-Hill, Inc.
3. Durbeej M, Campbell KP, (2002) Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. Current Opinion in Genetics & Development 12: 349-361.
4. Wrogemann K, Pena SDJ, (1976) Mitochondrial Calcium Overload: A General Mechanism for Cell-Necrosis in Muscle Disease. The Lancet 307: 672-674.
5. Bodensteiner JB, Engel AG, (1978) Intracellular calcium accumulation in Duchenne dystrophy and other myopathies: a study of 567,000 muscle fibers in 114 biopsies. Neurology 28: 439-446.
6. Arahata K, Engel AG, (1984) Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol 16: 193-208.
7. Emery AE, Muntoni F, (2003) Duchenne Muscular Dystrophy Oxford Oxford University Press.
8. Kohler M, Clarenbach CF, Bahler C, Brack T, Russi EW, et al. (2009) Disability and survival in Duchenne muscular dystrophy. J Neurol Neurosurg Psychiatry 80: 320-325.
9. Khurana TS, Hoffman EP, Kunkel LM, (1990) Identification of a chromosome 6-encoded dystrophin-related protein. J Biol Chem 265: 16717-16720.
10. Love DR, Hill DF, Dickson G, Spurr NK, Byth BC, et al. (1989) An autosomal transcript in skeletal muscle with homology to dystrophin. Nature 339: 55-58.
11. Matsumura K, Ervasti JM, Ohlendieck K, Kahl SD, Campbell KP, (1992) Association of dystrophin-related protein with dystrophin-associated proteins in mdx mouse muscle. Nature 360: 588-591.
12. Tinsley JM, Blake DJ, Roche A, Fairbrother U, Riss J, et al. (1992) Primary structure of dystrophin-related protein. Nature 360: 591-593.
13. Koenig M, Monaco AP, Kunkel LM, (1988) The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53: 219-228.
14. Love DR, Morris GE, Ellis JM, Fairbrother U, Marsden RF, et al. (1991) Tissue distribution of the dystrophin-related gene product and expression in the mdx and dy mouse. Proc Natl Acad Sci U S A 88: 3243-3247.
15. Burton EA, Tinsley JM, Holzfeind PJ, Rodrigues NR, Davies KE, (1999) A second promoter provides an alternative target for therapeutic up-regulation of utrophin in Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 96: 14025-14030.
16. Weir AP, Burton EA, Harrod G, Davies KE, (2002) A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. J Biol Chem 277: 45285-45290.
17. Gilbert R, Nalbantoglu J, Petrof BJ, Ebihara S, Guibinga GH, et al. (1999) Adenovirus-mediated utrophin gene transfer mitigates the dystrophic phenotype of mdx mouse muscles. Hum Gene Ther 10: 1299-1310.
18. Tinsley J, Deconinck N, Fisher R, Kahn D, Phelps S, et al. (1998) Expression of full-length utrophin prevents muscular dystrophy in mdx mice. Nat Med 4: 1441-1444.
19. Krag TO, Bogdanovich S, Jensen CJ, Fischer MD, Hansen-Schwartz J, et al. (2004) Heregulin ameliorates the dystrophic phenotype in mdx mice. Proc Natl Acad Sci U S A 101: 13856-13860.
20. Barton ER, Morris L, Kawana M, Bish LT, Toursel T, (2005) Systemic administration of L-arginine benefits mdx skeletal muscle function. Muscle Nerve 32: 751-760.
21. Voisin V, Sebrie C, Matecki S, Yu H, Gillet B, et al. (2005) L-arginine improves dystrophic phenotype in mdx mice. Neurobiol Dis 20: 123-130.
22. Sonnemann KJ, Heun-Johnson H, Turner AJ, Baltgalvis KA, Lowe DA, et al. (2009) Functional substitution by TAT-utrophin in dystrophin-deficient mice. PLoS Med 6: e1000083.
23. Lu Y, Tian C, Danialou G, Gilbert R, Petrof BJ, et al. (2008) Targeting artificial transcription factors to the utrophin A promoter: effects on dystrophic pathology and muscle function. J Biol Chem 283: 34720-34727.
24. DiMasi JA, (2001) Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 69: 297-307.
25. DiMasi JA, Hansen RW, Grabowski HG, (2003) The price of innovation: new estimates of drug development costs. Journal of Health Economics 22: 151-185.
26. Reichert JM, (2003) Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov 2: 695-702.
27. Ashburn TT, Thor KB, (2004) Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 3: 673-683.
28. Tobinick EL, (2009) The value of drug repositioning in the current pharmaceutical market. Drug News Perspect 22: 119-125.
29. Chong CR, Sullivan DJ, (2007) New uses for old drugs. Nature 448: 645-646.
30. Rothstein JD, Patel S, Regan MR, Haenggeli C, Huang YH, et al. (2005) [beta]-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 433: 73-77.
31. Baby SM, Bogdanovich S, Willmann G, Basu U, Lozynska O, et al. (2010) Differential Expression of Utrophin-A and-B Promoters in the Central Nervous System (CNS) of Normal and Dystrophic mdx Mice. pp. 323-342.
32. Chaubourt E, Fossier P, Baux G, Leprince C, Israel M, et al. (1999) Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy. Neurobiol Dis 6: 499-507.
33. Rodova M, Brownback K, Werle MJ, (2004) Okadaic acid augments utrophin in myogenic cells. Neurosci Lett 363: 163-167.
34. Khurana TS, Rosmarin AG, Shang J, Krag TO, Das S, et al. (1999) Activation of utrophin promoter by heregulin via the ets-related transcription factor complex GA-binding protein alpha/beta. Mol Biol Cell 10: 2075-2086.
35. Zhang JH, Chung TD, Oldenburg KR, (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
36. Ji DB, Zhu HB, Ye J, Li CL, (2008) Establishment of a cell-based assay to screen regulators of the hypoxia-inducible factor-1-dependent vascular endothelial growth factor promoter. Biol Pharm Bull 31: 2255-2259.
37. Jiang N, Ou-Yang KQ, Cai SX, Hu YH, Xu ZL, (2005) Identification of human dopamine D1-like receptor agonist using a cell-based functional assay. Acta Pharmacol Sin 26: 1181-1186.
38. Xu ZL, Gao H, Ou-Yang KQ, Cai SX, Hu YH, (2004) Establishment of a cell-based assay to screen regulators for Klotho gene promoter. Acta Pharmacol Sin 25: 1165-1170.
39. Auld DS, Thorne N, Nguyen D-T, Inglese J, (2008) A Specific Mechanism for Nonspecific Activation in Reporter-Gene Assays. ACS Chemical Biology 3: 463-470.
40. Khurana TS, Watkins SC, Chafey P, Chelly J, Tome FM, et al. (1991) Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. Neuromuscul Disord 1: 185-194.
41. Nguyen TM, Ellis JM, Love DR, Davies KE, Gatter KC, et al. (1991) Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. J Cell Biol 115: 1695-1700.
42. Ohlendieck K, Ervasti JM, Matsumura K, Kahl SD, Leveille CJ, et al. (1991) Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. Neuron 7: 499-508.
43. Aartsma-Rus A, Ivo F, Jan V, Ieke G, Judith van D, et al. (2009) Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations. pp. 293-299.
44. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, et al. (2007) PTC124 targets genetic disorders caused by nonsense mutations. Nature 447: 87-91.
45. Hoffman EP, (2007) Skipping toward Personalized Molecular Medicine pp. 2719-2722.
46. Koenig M, Hoffman EP, Bertelson CJ, Monaco AP, Feener C, et al. (1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517.
47. Lipinski CA, (2000) Drug-like properties and the causes of poor solubility and poor permeability. J Pharmacol Toxicol Methods 44: 235-249.
48. Di L, Kerns EH, (2003) Profiling drug-like properties in discovery research. Current Opinion in Chemical Biology 7: 402-408.
49. Laneuville O, Breuer DK, Dewitt DL, Hla T, Funk CD, et al. (1994) Differential inhibition of human prostaglandin endoperoxide H synthases-1 and-2 by nonsteroidal anti-inflammatory drugs. J Pharmacol Exp Ther 271: 927-934.
50. Hedner T, Samulesson O, Wahrborg P, Wadenvik H, Ung KA, et al. (2004) Nabumetone: therapeutic use and safety profile in the management of osteoarthritis and rheumatoid arthritis. Drugs 64: 2315-2343; discussion 2344-2315.
51. McDouall RM, Dunn MJ, Dubowitz V, (1990) Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J Neurol Sci 99: 199-217.
52. Chen YW, Nagaraju K, Bakay M, McIntyre O, Rawat R, et al. (2005) Early onset of inflammation and later involvement of TGFbeta in Duchenne muscular dystrophy. Neurology 65: 826-834.
53. Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528, 1522 p following 1528.
54. Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, et al. (2005) Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial. pp. 1092-1102.
55. Solomon SD, McMurray JJV, Pfeffer MA, Wittes J, Fowler R, et al. (2005) Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention. pp. 1071-1080.
56. FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ 2nd, et al. (1983) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71: 676-688.
57. Schulman SP, Becker LC, Kass DA, Champion HC, Terrin ML, et al. (2006) L-Arginine Therapy in Acute Myocardial Infarction: The Vascular Interaction With Age in Myocardial Infarction (VINTAGE MI) Randomized Clinical Trial. pp. 58-64.
58. U.S. National Library of Medicine NIoH (2010) Drugs & Supplements: L-arginine. Available: http://www.nlm.nih.gov/medlineplus/druginfo/natural/875.html. Accessed: 31st October 2010. MedlinePlus.
59. Gramolini AO, Belanger G, Jasmin BJ, (2001) Distinct regions in the 3′ untranslated region are responsible for targeting and stabilizing utrophin transcripts in skeletal muscle cells. J Cell Biol 154: 1173-1183.
60. Gramolini AO, Belanger G, Thompson JM, Chakkalakal JV, Jasmin BJ, (2001) Increased expression of utrophin in a slow vs. a fast muscle involves posttranscriptional events. Am J Physiol Cell Physiol 281: C1300-1309.
61. Miura P, Thompson J, Chakkalakal JV, Holcik M, Jasmin BJ, (2005) The utrophin A 5′-untranslated region confers internal ribosome entry site-mediated translational control during regeneration of skeletal muscle fibers. J Biol Chem 280: 32997-33005.
62. Rosenberg MI, Georges SA, Asawachaicharn A, Analau E, Tapscott SJ, (2006) MyoD inhibits Fstl1 and Utrn expression by inducing transcription of miR-206. J Cell Biol 175: 77-85.
63. Amenta AR, Yilmaz A, Bogdanovich S, McKechnie BA, Abedi M, et al. Biglycan recruits utrophin to the sarcolemma and counters dystrophic pathology in mdx mice. pp. 762-767.